8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Apr 16, 2026·SEC
Material company update
Feb 24, 2026·SEC
CareDx, Inc(CDNA)Earnings, Financials & Key Ratios
CDNA•NASDAQ
$20.94
$1.08B mkt cap·Price updated May 6, 2026
AboutCareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Show more
- Revenue$380M+13.8%
- EBITDA-$600K-101.0%
- Net Income-$21M-140.6%
- EPS (Diluted)-0.40-143.0%
- Gross Margin66.99%-0.2%
- EBITDA Margin-0.16%-100.9%
- Operating Margin-5.53%-145.3%
- Net Margin-5.62%-135.7%
- ROE-6.27%-138.1%
- ROIC-5.74%-147.4%
- Debt/Equity0.06-13.4%
CDNA Key Insights
CareDx, Inc (CDNA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 83 (top 17%)
- ✓Strong 5Y sales CAGR of 14.6%
- ✓Share count reduced 5.9% through buybacks
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CDNA Price & Volume
CareDx, Inc (CDNA) stock price & volume — 10-year historical chart
Loading chart...
CDNA Growth Metrics
CareDx, Inc (CDNA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years29.72%
5 Years14.59%
3 Years5.68%
TTM19.17%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-114.73%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-114.57%
Return on Capital
10 Years-26.43%
5 Years-13.34%
3 Years-14.34%
Last Year-5.8%
CDNA Recent Earnings
CareDx, Inc (CDNA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
Apr 28, 2026EPS
$0.34
Est $0.11
+209.1%
Revenue
$118M
Est $102M
+15.4%
Q1 2026
Feb 24, 2026EPS
$0.12
Est $0.02
+503.0%
Revenue
$108M
Est $103M
+5.0%
Q4 2025
Nov 4, 2025EPS
$0.28
Est $0.13
+115.4%
Revenue
$100M
Est $103M
-2.6%
Q3 2025
Aug 6, 2025EPS
$0.10
Est $0.12
-16.7%
Revenue
$87M
Est $95M
-9.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.34vs $0.11+209.1% | $118Mvs $102M+15.4% |
| Q1 2026 | Feb 24, 2026 | $0.12vs $0.02+503.0% | $108Mvs $103M+5.0% |
| Q4 2025 | Nov 4, 2025 | $0.28vs $0.13+115.4% | $100Mvs $103M-2.6% |
| Q3 2025 | Aug 6, 2025 | $0.10vs $0.12-16.7% | $87Mvs $95M-9.0% |
Based on last 12 quarters of dataView full earnings history →
CDNA Peer Comparison
CareDx, Inc (CDNA) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NTRA | 29.58B | 215.09 | -140.58 | 56.75% | -14.61% | -24.69% | 0.16 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 PACB | 516.17M | 1.71 | -1.60 | -23.19% | -325.8% | -13.95% | 1.33 | |
 ILMN | 21.66B | 142.58 | 26.16 | -0.78% | 19.43% | 32.84% | 0.94 | |
 TXMD | 23.5M | 2.03 | -10.68 | 35.25% | 10.8% | 1.1% | 0.26 | |
 FLGT | 443.83M | 14.92 | -7.57 | 13.83% | -18.75% | -5.42% | 0.00 | |
 VCYT | 3.29B | 41.19 | 50.23 | 16.01% | 16.25% | 6.86% | 0.03 | |
 PGNY | 1.53B | 18.70 | 28.77 | 10.4% | 4.54% | 11.37% | 0.05 |
Compare CDNA vs Peers
CareDx, Inc (CDNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CDNA Income Statement
CareDx, Inc (CDNA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 48.32M | 76.57M | 127.07M | 192.19M | 296.4M | 321.79M | 280.32M | 333.79M | 379.81M | 412.82M |
| Revenue Growth % | 18.93% | 58.45% | 65.95% | 51.25% | 54.22% | 8.57% | -12.89% | 19.07% | 13.79% | 19.17% |
| Cost of Goods Sold | 21.37M | 32.99M | 45.45M | 63.12M | 97.39M | 112.21M | 102M | 109.63M | 125.38M | 96.15M |
| COGS % of Revenue | 44.22% | 43.08% | 35.77% | 32.84% | 32.86% | 34.87% | 36.39% | 32.84% | 33.01% | - |
| Gross Profit | 26.95M▲ 0% | 43.58M▲ 61.7% | 81.61M▲ 87.3% | 129.08M▲ 58.2% | 199.01M▲ 54.2% | 209.58M▲ 5.3% | 178.32M▼ 14.9% | 224.16M▲ 25.7% | 254.43M▲ 13.5% | 198.97M▲ 0% |
| Gross Margin % | 55.78% | 56.92% | 64.23% | 67.16% | 67.14% | 65.13% | 63.61% | 67.16% | 66.99% | 48.2% |
| Gross Profit Growth % | 38.16% | 61.7% | 87.26% | 58.16% | 54.18% | 5.31% | -14.91% | 25.7% | 13.5% | - |
| Operating Expenses | 44.11M | 58.14M | 106.14M | 151.6M | 228.73M | 286.81M | 381.69M | 183.39M | 275.44M | 330.46M |
| OpEx % of Revenue | 91.28% | 75.94% | 83.53% | 78.88% | 77.17% | 89.13% | 136.16% | 54.94% | 72.52% | - |
| Selling, General & Admin | 31.72M | 43.63M | 75.43M | 102.66M | 152.21M | 196.42M | 201.2M | 205.5M | 210.21M | 225.31M |
| SG&A % of Revenue | 65.64% | 56.98% | 59.37% | 53.42% | 51.35% | 61.04% | 71.77% | 61.57% | 55.35% | - |
| Research & Development | 12.39M | 14.51M | 30.71M | 48.94M | 76.53M | 90.39M | 81.87M | 72.41M | 71.43M | 74.32M |
| R&D % of Revenue | 25.64% | 18.96% | 24.17% | 25.46% | 25.82% | 28.09% | 29.2% | 21.69% | 18.81% | - |
| Other Operating Expenses | 0 | -178K | 0 | 0 | 0 | 0 | 98.62M | -94.52M | -6.2M | -477K |
| Operating Income | -20.29M▲ 0% | -15.58M▲ 23.2% | -24.53M▼ 57.5% | -22.53M▲ 8.2% | -29.73M▼ 32.0% | -77.23M▼ 159.8% | -203.36M▼ 163.3% | 40.77M▲ 120.0% | -21.02M▼ 151.6% | -13.79M▲ 0% |
| Operating Margin % | -42% | -20.34% | -19.31% | -11.72% | -10.03% | -24% | -72.55% | 12.21% | -5.53% | -3.34% |
| Operating Income Growth % | 45.64% | 23.24% | -57.48% | 8.17% | -31.95% | -159.81% | -163.32% | 120.05% | -151.55% | - |
| EBITDA | -16.54M | -11.36M | -17.39M | -12.98M | -17.84M | -61.22M | -183.54M | 60.52M | -600K | 1.68M |
| EBITDA Margin % | -34.22% | -14.84% | -13.68% | -6.76% | -6.02% | -19.03% | -65.47% | 18.13% | -0.16% | 0.41% |
| EBITDA Growth % | 51.95% | 31.28% | -53.02% | 25.33% | -37.41% | -243.16% | -199.78% | 132.97% | -100.99% | -97.33% |
| D&A (Non-Cash Add-back) | 3.76M | 4.21M | 7.14M | 9.54M | 11.88M | 16.01M | 19.82M | 19.76M | 20.42M | 15.48M |
| EBIT | -18.34M | -15.58M | -24.53M | -17.71M | -29.73M | -77.23M | -104.74M | -53.75M | -21.08M | -12.52M |
| Net Interest Income | -5.86M | -3.7M | 985K | 271K | 160K | 3.76M | 11.87M | 11.77M | 9.17M | 6.39M |
| Interest Income | 0 | 0 | 985K | 271K | 160K | 3.76M | 11.87M | 11.77M | 9.17M | 6.39M |
| Interest Expense | 5.86M | 3.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -36.98M | -32.64M | 585K | 2.78M | -2.36M | 997K | 13.22M | 12.09M | -67K | 5.78M |
| Pretax Income | -57.27M▲ 0% | -48.22M▲ 15.8% | -23.95M▲ 50.3% | -19.75M▲ 17.5% | -32.09M▼ 62.5% | -76.23M▼ 137.6% | -190.14M▼ 149.4% | 52.86M▲ 127.8% | -21.08M▼ 139.9% | -8.01M▲ 0% |
| Pretax Margin % | -118.51% | -62.97% | -18.85% | -10.28% | -10.83% | -23.69% | -67.83% | 15.84% | -5.55% | -1.94% |
| Income Tax | -1.71M | -1.43M | -1.98M | -1.04M | -1.43M | 379K | 141K | 310K | 271K | 245K |
| Effective Tax Rate % | 2.98% | 2.97% | 8.26% | 5.25% | 4.44% | -0.5% | -0.07% | 0.59% | -1.29% | -3.06% |
| Net Income | -55.47M▲ 0% | -46.76M▲ 15.7% | -21.97M▲ 53.0% | -18.71M▲ 14.8% | -30.66M▼ 63.8% | -76.61M▼ 149.9% | -190.28M▼ 148.4% | 52.55M▲ 127.6% | -21.35M▼ 140.6% | -8.19M▲ 0% |
| Net Margin % | -114.79% | -61.06% | -17.29% | -9.74% | -10.34% | -23.81% | -67.88% | 15.74% | -5.62% | -1.98% |
| Net Income Growth % | -40.54% | 15.71% | 53.02% | 14.81% | -63.85% | -149.86% | -148.37% | 127.62% | -140.64% | -114.73% |
| Net Income (Continuing) | -55.56M | -46.78M | -21.97M | -18.71M | -30.66M | -76.61M | -190.28M | 52.55M | -21.35M | -8.19M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 180K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.38▲ 0% | -1.31▲ 45.0% | -0.52▲ 60.3% | -0.40▲ 23.1% | -0.59▼ 47.5% | -1.44▼ 144.1% | -3.54▼ 145.8% | 0.93▲ 126.3% | -0.40▼ 143.0% | -0.15▲ 0% |
| EPS Growth % | 0.42% | 44.96% | 60.31% | 23.08% | -47.5% | -144.07% | -145.83% | 126.27% | -143.01% | -114.57% |
| EPS (Basic) | -2.38 | -1.31 | -0.52 | -0.40 | -0.59 | -1.44 | -3.54 | 1.00 | -0.40 | - |
| Diluted Shares Outstanding | 23.33M | 35.64M | 42.15M | 46.48M | 52.24M | 53.32M | 53.76M | 56.62M | 53.29M | 53.13M |
| Basic Shares Outstanding | 23.31M | 35.64M | 42.15M | 46.48M | 52.24M | 53.32M | 53.76M | 52.77M | 53.29M | 51.15M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CDNA Balance Sheet
CareDx, Inc (CDNA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 26.77M | 81.11M | 71.92M | 273.1M | 433.36M | 387.85M | 313.71M | 351.83M | 257.13M | 269.39M |
| Cash & Short-Term Investments | 16.89M | 64.62M | 38.22M | 224.7M | 348.49M | 293.09M | 235.42M | 260.65M | 177.21M | 187.18M |
| Cash Only | 16.89M | 64.62M | 38.22M | 134.67M | 348.49M | 89.92M | 82.2M | 114.69M | 65.43M | 77.92M |
| Short-Term Investments | 0 | 0 | 0 | 90.03M | 0 | 203.17M | 153.22M | 145.96M | 111.78M | 109.25M |
| Accounts Receivable | 2.99M | 9.76M | 24.06M | 34.62M | 59.76M | 66.31M | 51.06M | 64.61M | 42.63M | 44.59M |
| Days Sales Outstanding | 22.59 | 46.53 | 69.1 | 65.76 | 73.59 | 75.22 | 66.48 | 70.65 | 40.97 | 44.74 |
| Inventory | 5.53M | 4.94M | 6.01M | 10.01M | 17.19M | 19.23M | 19.47M | 19.5M | 26.7M | 26.4M |
| Days Inventory Outstanding | 94.43 | 54.69 | 48.29 | 57.9 | 64.41 | 62.56 | 69.68 | 64.93 | 77.74 | 103.78 |
| Other Current Assets | 1.35M | 1.79M | 0 | 0 | 0 | 9.22M | 7.76M | 7.07M | 10.59M | 11.23M |
| Total Non-Current Assets | 56.8M | 49.58M | 79.81M | 95.41M | 133.26M | 155.14M | 153.11M | 139.22M | 156.1M | 141.67M |
| Property, Plant & Equipment | 2.08M | 4.13M | 9.16M | 25.93M | 40.04M | 70.22M | 65.14M | 57.89M | 55.73M | 54.36M |
| Fixed Asset Turnover | 23.29x | 18.52x | 13.87x | 7.41x | 7.40x | 4.58x | 4.30x | 5.77x | 6.81x | 7.43x |
| Goodwill | 12.01M | 12.01M | 23.86M | 23.86M | 36.98M | 37.52M | 40.34M | 40.34M | 40.34M | 40.34M |
| Intangible Assets | 33.14M | 33.25M | 45.54M | 44.35M | 50.2M | 43.05M | 45.7M | 38.18M | 31.96M | 32.1M |
| Long-Term Investments | 9.58M | 192K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | -2.64M | -3.49M | 1.26M | 1.27M | 6.05M | 4.35M | 1.94M | 2.81M | 28.07M | 49.57M |
| Total Assets | 83.56M▲ 0% | 130.7M▲ 56.4% | 151.74M▲ 16.1% | 368.51M▲ 142.9% | 566.62M▲ 53.8% | 542.99M▼ 4.2% | 466.83M▼ 14.0% | 491.05M▲ 5.2% | 413.23M▼ 15.8% | 411.06M▲ 0% |
| Asset Turnover | 0.58x | 0.59x | 0.84x | 0.52x | 0.52x | 0.59x | 0.60x | 0.68x | 0.92x | 0.97x |
| Asset Growth % | 8.91% | 56.4% | 16.1% | 142.86% | 53.76% | -4.17% | -14.03% | 5.19% | -15.85% | -46.09% |
| Total Current Liabilities | 42.91M | 19.5M | 34.83M | 69.22M | 77.3M | 75.97M | 78.07M | 89.37M | 89.85M | 79.15M |
| Accounts Payable | 3.39M | 4.71M | 5.51M | 9.65M | 13.34M | 9.94M | 12.87M | 7.69M | 9.99M | 9.07M |
| Days Payables Outstanding | 57.92 | 52.13 | 44.21 | 55.82 | 49.99 | 32.34 | 46.06 | 25.59 | 29.08 | 38.45 |
| Short-Term Debt | 15.72M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 39K | 39K | 3.69M | 24.03M | 4.21M | 5.34M | 4.75M | 4.85M | 0 | 5.95M |
| Other Current Liabilities | 18.77M | 9.16M | 15.39M | 21.2M | 32.77M | 21.3M | 26.24M | 41.12M | 79.86M | 70.09M |
| Current Ratio | 0.62x | 4.16x | 2.07x | 3.95x | 5.61x | 5.10x | 4.02x | 3.94x | 2.86x | 2.86x |
| Quick Ratio | 0.49x | 3.91x | 1.89x | 3.80x | 5.38x | 4.85x | 3.77x | 3.72x | 2.56x | 2.56x |
| Cash Conversion Cycle | 59.11 | 49.09 | 73.18 | 67.83 | 88.02 | 105.43 | 90.1 | 109.99 | 89.63 | 110.07 |
| Total Non-Current Liabilities | 46.61M | 15.27M | 17.91M | 21.61M | 23.44M | 36.1M | 127.43M | 23.25M | 20.28M | 18.37M |
| Long-Term Debt | 18.34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17.84M |
| Capital Lease Obligations | 0 | 0 | 2.37M | 16.07M | 17.39M | 33.41M | 28.28M | 22.26M | 19.68M | 63.67M |
| Deferred Tax Liabilities | 4.93M | 2.97M | 1.97M | 1.3M | 415K | 0 | 136K | 164K | 181K | 442K |
| Other Non-Current Liabilities | 22.61M | 11.61M | 13.56M | 4.25M | 5.63M | 2.7M | 99.01M | 819K | 418K | 2.53M |
| Total Liabilities | 89.52M | 34.77M | 52.74M | 90.83M | 100.75M | 112.08M | 205.5M | 112.62M | 110.13M | 97.53M |
| Total Debt | 34.06M | 172K | 5.39M | 18.1M | 21.35M | 39M | 34.22M | 28.37M | 19.68M | 17.84M |
| Net Debt | 17.16M | -64.44M | -32.84M | -116.57M | -327.13M | -50.92M | -47.98M | -86.32M | -45.75M | -60.09M |
| Debt / Equity | - | 0.00x | 0.05x | 0.07x | 0.05x | 0.09x | 0.13x | 0.07x | 0.06x | 0.06x |
| Debt / EBITDA | - | - | - | - | - | - | - | 0.47x | - | 10.61x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | -1.43x | - | -35.74x |
| Interest Coverage | -3.13x | -4.21x | - | - | - | - | - | - | - | - |
| Total Equity | -5.95M▲ 0% | 95.93M▲ 1711.2% | 99M▲ 3.2% | 277.68M▲ 180.5% | 465.88M▲ 67.8% | 430.91M▼ 7.5% | 261.33M▼ 39.4% | 378.43M▲ 44.8% | 303.1M▼ 19.9% | 313.54M▲ 0% |
| Equity Growth % | -130.13% | 1711.15% | 3.2% | 180.48% | 67.77% | -7.51% | -39.35% | 44.81% | -19.91% | 0.3% |
| Book Value per Share | -0.26 | 2.69 | 2.35 | 5.97 | 8.92 | 8.08 | 4.86 | 6.68 | 5.69 | 5.90 |
| Total Shareholders' Equity | -6.13M | 95.93M | 99M | 277.68M | 465.88M | 430.91M | 261.33M | 378.43M | 303.1M | 313.54M |
| Common Stock | 29K | 41K | 42K | 49K | 52K | 52K | 49K | 51K | 50K | 51K |
| Retained Earnings | -268.02M | -311.85M | -333.81M | -352.53M | -383.19M | -460.44M | -678.27M | -626.24M | -735.36M | -732.55M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.35M | -4.28M | -5.21M | -2.1M | -4.67M | -7.5M | -6.96M | -8.57M | -5.51M | -6.27M |
| Minority Interest | 180K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CDNA Cash Flow Statement
CareDx, Inc (CDNA) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -14.31M | -4.01M | -2.77M | 33.43M | -19.29M | -25.24M | -18.39M | 38.05M | 42.03M | 42.03M |
| Operating CF Margin % | -29.61% | -5.23% | -2.18% | 17.39% | -6.51% | -7.84% | -6.56% | 11.4% | 11.07% | - |
| Operating CF Growth % | 13.41% | 71.99% | 30.9% | 1307.33% | -157.71% | -30.81% | 27.14% | 306.92% | 10.47% | 264.45% |
| Net Income | -55.56M | -46.78M | -21.97M | -18.71M | -30.66M | -76.61M | -190.28M | 52.55M | -21.35M | -8.19M |
| Depreciation & Amortization | 3.76M | 4.21M | 7.14M | 9.54M | 11.88M | 16.01M | 19.82M | 19.76M | 20.42M | 20.79M |
| Stock-Based Compensation | 1.74M | 7.14M | 22.42M | 23.4M | 36.08M | 46.55M | 49.09M | 66.41M | 34.86M | 35.74M |
| Deferred Taxes | -2.09M | -1.61M | 0 | 0 | 0 | 0 | 566K | -187K | 17K | 17K |
| Other Non-Cash Items | 38.97M | 33.9M | 51K | 1.8M | 4.37M | 3.03M | -3.61M | 1.83M | 4.28M | -10.19M |
| Working Capital Changes | -1.13M | -871K | -10.41M | 17.4M | -40.97M | -14.22M | 106.03M | -102.31M | 3.81M | 34.78M |
| Change in Receivables | -109K | -3.97M | -12.68M | -10.4M | -24.42M | -6.66M | 16.02M | -13.74M | 22.52M | 27.08M |
| Change in Inventory | 1.02M | 363K | -1.27M | -3.2M | -6.93M | -2.86M | 54K | -1.02M | -4.96M | -2.63M |
| Change in Payables | 292K | -168K | 1.35M | 4.39M | 1.79M | -2.05M | 2.9M | -5.11M | 808K | 93K |
| Cash from Investing | -6.16M | -7.93M | -22.58M | -100.39M | 47.71M | -228.5M | 40.45M | -483K | 2.16M | 11.89M |
| Capital Expenditures | -186K | -7.24M | -3.35M | -10.36M | -20.26M | -24.33M | -9.24M | 0 | -6.59M | -8.78M |
| CapEx % of Revenue | 0.38% | 9.45% | 2.64% | 5.39% | 6.84% | 7.56% | 3.3% | 1.94% | 1.73% | - |
| Acquisitions | -5.92M | -692K | -18.23M | 0 | -15.43M | -610K | -6.68M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -59K | -5.2M | 0 | 0 | 0 | 0 | 1.5M | -7.12M | 0 | 0 |
| Cash from Financing | 29.38M | 50.27M | -132K | 163.15M | 185.64M | -4.54M | -29.61M | -5.61M | -93.39M | -95.66M |
| Debt Issued (Net) | 9.71M | -14.48M | -172K | -183K | -66K | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | -698K | 0 | 158.13M | 188.85M | -642K | -27.54M | -522K | -79.77M | -86.12M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -642K | -27.54M | -522K | -87.77M | -86.78M |
| Other Financing | 19.67M | 65.45M | 40K | 5.2M | -3.15M | -3.89M | -2.06M | -5.08M | -13.62M | -9.54M |
| Net Change in Cash | -363K▲ 0% | 38.33M▲ 10660.3% | -26.33M▼ 168.7% | 96.46M▲ 466.4% | 213.76M▲ 121.6% | -258.25M▼ 220.8% | -7.66M▲ 97.0% | 32.49M▲ 524.2% | -49.29M▼ 251.7% | -10.82M▲ 0% |
| Free Cash Flow | -14.49M▲ 0% | -11.24M▲ 22.4% | -6.12M▲ 45.6% | 23.07M▲ 477.1% | -39.55M▼ 271.4% | -49.57M▼ 25.3% | -27.63M▲ 44.3% | 31.56M▲ 214.2% | 36.12M▲ 14.4% | 65.19M▲ 0% |
| FCF Margin % | -29.99% | -14.68% | -4.81% | 12% | -13.34% | -15.41% | -9.86% | 9.46% | 9.51% | 15.79% |
| FCF Growth % | 15.11% | 22.42% | 45.59% | 477.1% | -271.44% | -25.33% | 44.27% | 214.25% | 14.43% | 223.53% |
| FCF per Share | -0.62 | -0.32 | -0.15 | 0.50 | -0.76 | -0.93 | -0.51 | 0.56 | 0.68 | 0.68 |
| FCF Conversion (FCF/Net Income) | 0.26x | 0.09x | 0.13x | -1.79x | 0.63x | 0.33x | 0.10x | 0.72x | -1.97x | -7.96x |
| Interest Paid | 0 | 0 | 22K | 10K | 1K | 8K | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 80K | 14K | 392K | 738K | 317K | 0 | 0 |
CDNA Key Ratios
CareDx, Inc (CDNA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -803.49% | -103.93% | -22.54% | -9.94% | -8.25% | -17.09% | -54.98% | 16.43% | -6.27% | -2.61% |
| Return on Invested Capital (ROIC) | -80.84% | -54.73% | -37.68% | -14.87% | -14.87% | -22.33% | -51.41% | 12.1% | -5.74% | -5.74% |
| Gross Margin | 55.78% | 56.92% | 64.23% | 67.16% | 67.14% | 65.13% | 63.61% | 67.16% | 66.99% | 48.2% |
| Net Margin | -114.79% | -61.06% | -17.29% | -9.74% | -10.34% | -23.81% | -67.88% | 15.74% | -5.62% | -1.98% |
| Debt / Equity | - | 0.00x | 0.05x | 0.07x | 0.05x | 0.09x | 0.13x | 0.07x | 0.06x | 0.06x |
| Interest Coverage | -3.13x | -4.21x | - | - | - | - | - | - | - | - |
| FCF Conversion | 0.26x | 0.09x | 0.13x | -1.79x | 0.63x | 0.33x | 0.10x | 0.72x | -1.97x | -7.96x |
| Revenue Growth | 18.93% | 58.45% | 65.95% | 51.25% | 54.22% | 8.57% | -12.89% | 19.07% | 13.79% | 19.17% |
CDNA SEC Filings & Documents
CareDx, Inc (CDNA) SEC filings — annual & quarterly reports (10-K, 10-Q)
CDNA Frequently Asked Questions
CareDx, Inc (CDNA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
CareDx, Inc (CDNA) reported $412.8M in revenue for fiscal year 2025. This represents a 1919% increase from $20.5M in 2012.
CareDx, Inc (CDNA) grew revenue by 13.8% over the past year. This is steady growth.
CareDx, Inc (CDNA) reported a net loss of $8.2M for fiscal year 2025.
Dividend & Returns
CareDx, Inc (CDNA) has a return on equity (ROE) of -6.3%. Negative ROE indicates the company is unprofitable.
CareDx, Inc (CDNA) generated $65.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More CDNA
CareDx, Inc (CDNA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates